Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + irinotecan
- Development stage
- Unknown
- Lead developer
- National Cancer Center Korea
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + irinotecan is a combination chemotherapy regimen evaluated by the National Cancer Center, Korea, for the treatment of recurrent or refractory bone and soft tissue sarcomas, including Ewing sarcoma. Docetaxel is a small molecule taxane that binds to and stabilizes microtubules, preventing their depolymerization and leading to cell cycle arrest at the G2/M phase. Irinotecan is a small molecule prodrug that is converted to its active metabolite, SN-38, which inhibits DNA topoisomerase I, causing double-strand DNA breaks and subsequent apoptosis. This combination therapy was specifically investigated in a Phase 2 clinical trial (NCT01380275) targeting patients under 50 years of age with advanced sarcomas.
- Brand names
- CamptosarTaxotere
- Other names
- docetaxel and irinotecan
02
Targets
TUBB (Tubulin (alpha and beta subunits))TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on docetaxel + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + irinotecan.